Kynurenine metabolism in Alzheimer's disease

Journal of Neural Transmission

Volumn 106, Issue 2, 1999, Pages 165-181

  Baran, H ^a   Jellinger, K ^a   Deecke, L ^b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Alzheimer's disease; Biosynthesis; Kynurenic acid; Kynurenine; Kynurenine aminotransferase

Indexed keywords

3 HYDROXYKYNURENINE; EXCITATORY AMINO ACID RECEPTOR; KYNURENIC ACID; KYNURENINE; KYNURENINE AMINOTRANSFERASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PYRUVIC ACID;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; LEARNING; MALE; MEMORY; METABOLISM; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BLOCKING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CAUDATE NUCLEUS; FEMALE; HUMANS; KINETICS; KYNURENIC ACID; KYNURENINE; LYASES; MALE; MATCHED-PAIR ANALYSIS; NEURODEGENERATIVE DISEASES; PYRUVIC ACID; TRANSAMINASES;

EID: 0033058001     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050149     Document Type: Article

References (86)

1. Arai H, Kobayashi K, Ichimiya Y, Kosaka K, Iizuka R (1984) A preliminary study of free amino acids in the postmortem temporal cortex from Alzheimer-Type dementia patients. Neurobiol Aging 5: 319-321
2. Arnold SE, Hyman BT, Van Hoesen GW, Damasio AR (1991) Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 48: 625-632
3. Baran H, Löscher W, Mevissen M (1994a) The glycine /NMDA receptor partial agonist D-cycloscrine blocks kainate-induced seizures in rats. Comparison with MK-801 and diazepam. Brain Res 652: 195-200
4. Baran H, Okuno E, Kido R, Schwarcz R (1994b) Purification and characterization of kynurenine aminotransferase I from human brain. J Neurochem 62: 730-738
5. Baran H, Gramer M, Hönack D, Löscher W (1995) Systemic administration of kainate induces marked increse of endogenous kynurenic acid in various brain regions and plasma of rats. Eur J Pharmacol 286: 167-175
6. Baran H, Cairns N, Lubec B, Lubec G (1996) Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. Life Sci 58: 1891-1899
7. Beach TG, Walker R, McGeer EG (1989) Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 2: 420-436
8. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED (1990) Kynureninc pathway measurements in Huntington's disease striatum: evidence for reduced fromation of kynurenic acid. J Neurochem 55: 1327-1339
9. Beal MF, Swartz KJ, Hyman BT, Storey E, Finn SF, Koroshetz W (1991) Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechnism. J Neurochem 57: 1068-1073
10. Birch PJ, Grossman CJ, Hayes AG (1988) Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 154: 85-87
11. Bliss TVP, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39
12. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem 72: 248-254
13. 6 and steroid hormone. Am J Clin Nutr 24: 243-247
14. Carter AJ (1992) Glycine antagonists: regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site. Drugs Future 17: 595-613
15. Cascella NG, Macciardi F, Cavallini C, Smelardi E (1994) d-Cycloserine adjuvant therapy co conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm 95: 105-111
16. Chessell IP, Procter AW, Francis PT, Bowen DM (1991) D-Cycloserine, a putative cognitive enhancer, facilities activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res 565: 345-348
17. Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, Moroni F (1995) Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J Neurochem 65: 1176-1183
18. Collingridge CL, Bliss TVP (1987) NMDA receptors-their role in long term potentiation. Trends Neurosci 10: 288-293
19. Danysz W, Wroblewski JT, Costa E (1988) Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology 27: 653-656
20. Davies P (1979) Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 171: 319-327
21. Du F, Schmidt W, Okuno E, Kido R, Köhler C, Schwarcz R (1992) Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J Comp Neurol 321: 477-487
22. Du F, Eid T, Schwarcz R (1998) Neuronal damage after the injection of aminooxyacetic acid into the rat entorhinal cortex: a silver impregnation study. Neuroscience 82: 1165-1178
23. Eastman CL, Guilarte TR (1989) Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res 495: 225-231
24. Ellison DW, Beal MF, Mazurek MF, Bird ED, Martin JB (1986) A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Ann Neurol 20: 616-621
25. Foster AC, Vezzani A, French ED, Schwarcz R (1984) Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 48: 273-278
26. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56: 2007-2017
27. Gal EM, Scherman AD (1978) Synthesis and metabolism of L-kynurenine in rat brain. J Neurochem 30: 607-613
28. Gramsbergen JBP, Schmidt W, Turski WA, Schwarcz R (1992) Age-related changes in kynurenic acid production in rat brain. Brain Res 588: 1-5
29. Guidetti P, Okuno E, Schwarcz R (1997) Characterization of rat brain kynurenine aminotransferase I and II. J Neurosci Res 50: 457-465
30. Hardy J, Cowburn R, Barton A, Reynolds G, Lofdahl E, O'Carroll A-M, Wester P, Winblad B (1987) Region-specific loss of glutamate innervation in Alzheimer's disease. Neurosci Lett 73: 77-80
31. Heffernan JM, Eastwood SL, Nagy S, Sanders MW, McDonald B, Harrison PJ (1998) Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severitiy of dementia. Exp Neurol 150: 235-239
32. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJP, Lackner A, Larsen SA, Lee K, Leonard HL, Markey SP, Martin A, Milstein S, Mouradian MM, Pranzatelli MR, Quearry BJ, Salazar A, Smith M, Strauss SE, Sunderland T, Swedo SW. Tourtellotte WW (1992) Quinolinic acid and kinurenne pathway metabolism in inflammatory and non-inflamatory neurological disease Brain 115: 1249-1273
33. Hlinak T, Krejci I (1995) Kynurenic acid and 5,7-dichlorokynurenic acids improve social and object recognition in male rats. Psychopharmacology 120: 463-469
34. Hyman BT, Kromer LJ, Van Hoesen GW (1987) Reinnervation of the hippocampal perforant pathway zone in Alzheimer's dissease. Ann Neurol 21: 259-267
35. Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH (1995) Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol 52: 379-391
36. Jauch D, Urbanska FM, Guidetti P, Bird ED, Vonsattel JPG, Whetsell WO Jr, Schwarcz R (1995) Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci 130: 39-47
37. Jellinger K (1998) The neuropathological diagnosis of Alzheimer disease. J Neural Transm [Suppl] 53: 97-118
38. Jhamandas K, Boegman RJ, Beninger RJ, Bialik M (1990) Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res 529: 185-191
39. Johnson JW, Ascher P (1987) Glycine potentiates the NMDA respose in cultured mouse brain neurons. Nature 325: 529-531
40. Kemper TL (1978) Senile dementia: a focal disease in the temporal lobe. In: Nandy K (ed) Senile dementia: a biomedical approach. Elsevier, Amsterdam, pp 105-113
41. Lassmann H, Fischer P, Jellinger K (1993) Synaptic pathology of Alzheimer's disease. Ann NY Acad Sci 695: 59-64
42. Lapin IP (1981) Kynurenines and seizures. Epilepsia 22: 257-265
43. Mann DMA, Yates PO (1986) Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum Neurobiol 5: 147-158
44. Mason M (1954) The kynurenine transaminase of rat kidney. J Biol Chem 211: 839-844
45. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944
46. McMaster OG, DU F, French ED, Schwarcz R (1991) Focal injection of aminooxyacetic acid produces seizures and lesions in rat hippocampus: evidence for mediation by NMDA receptors. Exp Neurol 113: 367-374
47. McMaster OG, Baran H, Wu H-Q, Du F, French ED, Schwarcz R (1993) γ-Acetylenic GABA produces axon-sparing neurodegeneration after focal injection into the rat hippocampus. Exp Neurol 124: 184-191
48. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). II. Standardisation of the neuropathological assessment of Alzheimer's disease. Neurology 41: 479-486
49. Monahan JB, Handelmann GE, Hood WF, Cordi AA (1989) D-cycloserine, a positive modulator of the N-Methyl-D-aspatrate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav 34: 649-653
50. Morris RGM, Anderson E, Lynch GS, Baundry M (1986) Selective impairment of lerning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319: 774-776
51. Moroni F, Lombardi G, Robitaille Y, Etienne P (1986) Senile dementia and Alzheimer's disease: lack of changes of the cortical content of quinolinic acid. Neurobiol Aging 7: 249-253
52. Moroni F, Russi P, Lombardi G, Beni M, Carla V (1988) Kynurenic acid in the mammalian brain increases during the aging process or after the administration of its precursors. In: Cavalheiro EA, Lehmann J, Turski L (eds) Frontiers in excitatory amino acid research. AR Liss, New York, pp 629-636
53. Moroni F, Russi P, Carla V, De Luca G, Politi V (1991) The regulation of brain kynurenic acid content: focus on indole-3-pyruvic acid. In: Schwarcz R, Young SN, Broun RR (eds) Kynurenine and serotonin pathways progress in tryptophan research. Plenum Press, New York London, pp 299-308 (Adv Exp Med Biol 294)
54. Mouradian MM, Heyes MP, Pan J-B, Heuser IJE, Markey SP, Chase TN (1989) No changes in central quinolinic acid levels in Alzheimer's disease. Neurosci Lett 105: 233-238
55. Muller D, Joly M, Lynch G (1989) Contributions of quisqualate and NMDA receptors to the induction and expression of LTP. Science 242: 1694-1697
56. Nakamura M, Kawai J, Minatogawa Y, Kido R (1987) The metabolic degradation of kynurenine at tissue level by rat. In: Progress in tryptophan and serotonin research 1986, 1987. Walter de Gruyter, Berlin New York, pp 55-58
57. Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, Saso S (1992) Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42: 1702-1706
58. Okuno E, Du F, Ishikawa T, Tsujimoto M, Nakamura M, Schwarcz R, Kido R (1990) Purification and characterization of kynurenine-pyruvate aminotransferase from rat kidney and brain. Brain Res 534: 37-44
59. Okuno E, Nakamura M, Schwarcz R (1991a) Two kynurenine aminotransferases in human brain. Brain Res 542: 307-312
60. Okuno E, Schmidt W, Parks DA, Nakamura M, Schwarcz R (1991b) Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations. J Neurochem 57: 533-540
61. Pearson SJ, Reynolds GP (1992) Increased brain concentrations of a neurotoxin, 3-hydroxy-kynurenine, in Huntington's disease. Neurosci Lett 144: 199-201
62. Pittaluga A, Pattarini R, Raiteri M (1995) Putative cognition enhancers reverse kynurenic acid antagonism at hippocampal NMDA receptors. Eur J Pharmacol 272: 203-209
63. Politi V, Lavaggi MV, Di Stazio G, Margonelli A (1991) Indole-3-pyruvic acid as a direct precursor of kynurenic acid. In: Schwarcz R, Young SN, Broun RR (eds) Kynurenine and serotonin pathways progress in tryptophan research. Plenum Press, New York London, pp 515-518 (Adv Exp Med Biol 294)
64. 3H]MK-801 binding in Alzheimer's disease. J Neurochem 53: 698-704
65. Roberts RC, Du F, McCarthy KE, Okuno E, Schwarcz R (1992) Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: a light and electron microscopic study. J Comp Neurol 326: 82-90
66. Schwarcz R (1992) Excitotoxins, kynurenines and neuropsychiatric diseases: implications for drug development. In: Schousboe A, Diemer NH, Kofod H (eds) Drug research related to neuroactive amino acids. Munksgaard, Copenhagen, pp 287-301
67. Schwarcz R, Köhler Ch (1983) Differential vulnerability of central neurones of the rat to quinolinic acid. Neurosci Lett 38: 85-90
68. Schwarcz R, Price DL (1991) The role of excitotoxins in experimental systems and in human neurological disorders. In: Price DL, Thoenen H, Aguayo AJ (eds) Neurodegenerative disorders: mechanisms and prospects for therapy. John Wiley, Chiehester, pp 21-34
69. Schwarcz R, Du F, Gao X-M, Taminga CA (1990) Neurotoxicity of EAA antagonists: implications for schizophrenia research. American College of Neuropsychopharmacology Meeting, San Juan, Puerto Rico, Abstract, p 83
70. 3H]kynurenine as a substrate. Neuroscience 55: 177-184
71. Skong I, Wallin a, Fredman P, Hesse C, Aevarsson O, Karlsson I, Gottfries OG, Blennow K (1998) A population study on blood-brain barrier function in 85 year-olds. Relation to Alzheimer's disease and vascular dementia. Neurology 50: 966-971
72. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45: 309-379
73. Storga D, Vrecko K, Birkmayer JGD, Reibnegger G (1996) Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett 203: 29-32
74. Swartz KJ, Matson WR, MacGarvey U, Ryan EA, Beal MF (1990) Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. Ann Biochem 185: 363-376
75. Takahashi H, Kaihara M, Price JM (1956) The conversion of kynurenic acid to quinaldic acid by human and rats. J Biol Chem 223: 705-708
76. Tang JP, Melethil S (1995) Effect of aging on the kinetics of blood-brain barrier uptake of tryptophan in rats. Pharmac Res 12: 1085-1091
77. Terry RD, Masliah E, Salmon DP (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580
78. Tohgi H, Abe T, Takahashi S, Saheki M, Kimura M (1995) Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administation of citalopram, a synthetic serotonin uptake inhibitor. J Neural Transm [PD Sect] 9: 121-131
79. Tomlinson BE, Corsellis JAN (1984) Ageing and the dementias. In: Hume Adams J, Corsellis JAN, Duchen LW (eds) Greenfield's neuropathology. Edward Arnold, London, pp 951-1025
80. Tierney MC, Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW, Nicuwstraten P, Van Rooijen LAA, Derks HJGM, Van Wijk R, Bischop A (1988) The NINCDS-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer's disease. Neurology 38: 359-364
81. Turski WA, Schwarcz R (1988) On the disposition of intrahippocampally injected kynurenic acid in the rat. Exp Brain Res 71: 563-567
82. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO Jr, Schwarcz R (1988) Identification and quantification of kynurenic acid in human brain tissue. Brain Res 454: 164-169
83. Vecsei L, Miller J, MacGarvey U, Beal MF (1992a) Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid. Neurodegeneration 1: 17-26
84. Vecsei L, Miller J, MacGarvey U, Beal MF (1992b) Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res Bull 28: 233-238
85. Wesnes K, Jones RW, Kirby J (1991) The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia. Br J Clin Pharmacol 31: 577P-578P
86. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down syndrome. Ann Neurol 17: 278-282